AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
loteprednol etabonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| prednisone and prednisolone derivatives | 1611 | 82034-46-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 40 | |||
| kinase-selectivity-class | AXL,GRK2,MAP2K6,STK33 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 9, 1998 | FDA | BAUSCH AND LOMB |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Eye irritation | 284 | 19.70 | 93 | 4335 | 33885 | 90590134 |
| Eye pain | 215.51 | 19.70 | 81 | 4347 | 44087 | 90579932 |
| Ocular hyperaemia | 154.01 | 19.70 | 59 | 4369 | 33739 | 90590280 |
| Intraocular pressure increased | 136.31 | 19.70 | 37 | 4391 | 7056 | 90616963 |
| Vision blurred | 100.15 | 19.70 | 64 | 4364 | 110229 | 90513790 |
| Eye pruritus | 75.56 | 19.70 | 34 | 4394 | 28993 | 90595026 |
| Foreign body sensation in eyes | 71.82 | 19.70 | 19 | 4409 | 3281 | 90620738 |
| Dry eye | 71.59 | 19.70 | 41 | 4387 | 57890 | 90566129 |
| Lacrimation increased | 71.39 | 19.70 | 32 | 4396 | 27030 | 90596989 |
| Corneal oedema | 66.51 | 19.70 | 16 | 4412 | 1885 | 90622134 |
| Cataract | 60.86 | 19.70 | 40 | 4388 | 72052 | 90551967 |
| Punctate keratitis | 51.15 | 19.70 | 11 | 4417 | 785 | 90623234 |
| Photophobia | 49.33 | 19.70 | 23 | 4405 | 21246 | 90602773 |
| Visual acuity reduced | 47.22 | 19.70 | 23 | 4405 | 23387 | 90600632 |
| Ocular discomfort | 43.47 | 19.70 | 15 | 4413 | 6355 | 90617664 |
| Dacryostenosis acquired | 40.24 | 19.70 | 9 | 4419 | 770 | 90623249 |
| Endophthalmitis | 39.76 | 19.70 | 13 | 4415 | 4672 | 90619347 |
| Eye swelling | 34.16 | 19.70 | 20 | 4408 | 29366 | 90594653 |
| Eye inflammation | 33.20 | 19.70 | 13 | 4415 | 7838 | 90616181 |
| Ulcerative keratitis | 31.00 | 19.70 | 10 | 4418 | 3443 | 90620576 |
| Visual impairment | 30.66 | 19.70 | 35 | 4393 | 132330 | 90491689 |
| Product dose omission issue | 29.72 | 19.70 | 52 | 4376 | 291635 | 90332384 |
| Instillation site pain | 28.31 | 19.70 | 7 | 4421 | 923 | 90623096 |
| Corneal defect | 28.07 | 19.70 | 4 | 4424 | 23 | 90623996 |
| Corneal scar | 27.60 | 19.70 | 5 | 4423 | 146 | 90623873 |
| Corneal disorder | 27.18 | 19.70 | 8 | 4420 | 2034 | 90621985 |
| Cystoid macular oedema | 26.96 | 19.70 | 8 | 4420 | 2092 | 90621927 |
| Conjunctivitis allergic | 25.82 | 19.70 | 7 | 4421 | 1325 | 90622694 |
| Diffuse lamellar keratitis | 24.70 | 19.70 | 3 | 4425 | 3 | 90624016 |
| Uveitis | 24.42 | 19.70 | 13 | 4415 | 15890 | 90608129 |
| Glaucoma | 23.78 | 19.70 | 14 | 4414 | 20741 | 90603278 |
| Giant papillary conjunctivitis | 23.49 | 19.70 | 3 | 4425 | 6 | 90624013 |
| Hypopyon | 23.45 | 19.70 | 6 | 4422 | 908 | 90623111 |
| Abnormal sensation in eye | 23.11 | 19.70 | 7 | 4421 | 1964 | 90622055 |
| Corneal infection | 22.72 | 19.70 | 4 | 4424 | 99 | 90623920 |
| Undifferentiated connective tissue disease | 21.33 | 19.70 | 4 | 4424 | 142 | 90623877 |
| Corneal thickening | 20.30 | 19.70 | 3 | 4425 | 23 | 90623996 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Eye irritation | 107.62 | 26.27 | 32 | 1539 | 11286 | 42608478 |
| Eye pain | 106.74 | 26.27 | 35 | 1536 | 16995 | 42602769 |
| Intraocular pressure increased | 87.23 | 26.27 | 24 | 1547 | 6409 | 42613355 |
| Ulcerative keratitis | 53.81 | 26.27 | 13 | 1558 | 2075 | 42617689 |
| Vision blurred | 48.38 | 26.27 | 28 | 1543 | 53671 | 42566093 |
| Corneal oedema | 46.97 | 26.27 | 11 | 1560 | 1537 | 42618227 |
| Corneal perforation | 37.77 | 26.27 | 7 | 1564 | 311 | 42619453 |
| Dacryostenosis acquired | 37.69 | 26.27 | 7 | 1564 | 315 | 42619449 |
| Visual impairment | 34.92 | 26.27 | 21 | 1550 | 43092 | 42576672 |
| Ocular hyperaemia | 34.23 | 26.27 | 15 | 1556 | 15948 | 42603816 |
| Diffuse lamellar keratitis | 34.07 | 26.27 | 4 | 1567 | 4 | 42619760 |
| Corneal deposits | 33.14 | 26.27 | 6 | 1565 | 234 | 42619530 |
| Photophobia | 32.64 | 26.27 | 12 | 1559 | 8107 | 42611657 |
| Corneal dystrophy | 31.08 | 26.27 | 5 | 1566 | 95 | 42619669 |
| Corneal disorder | 29.38 | 26.27 | 7 | 1564 | 1052 | 42618712 |
| Corneal striae | 29.20 | 26.27 | 4 | 1567 | 23 | 42619741 |
| Corneal infiltrates | 28.22 | 26.27 | 5 | 1566 | 172 | 42619592 |
| Corneal opacity | 27.04 | 26.27 | 6 | 1565 | 659 | 42619105 |
| Corneal graft rejection | 26.58 | 26.27 | 4 | 1567 | 48 | 42619716 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Eye irritation | 258.31 | 19.10 | 84 | 4758 | 33368 | 110551089 |
| Eye pain | 228.76 | 19.10 | 85 | 4757 | 50014 | 110534443 |
| Intraocular pressure increased | 146.80 | 19.10 | 42 | 4800 | 10834 | 110573623 |
| Ocular hyperaemia | 127.24 | 19.10 | 52 | 4790 | 39234 | 110545223 |
| Vision blurred | 107.24 | 19.10 | 68 | 4774 | 128954 | 110455503 |
| Corneal oedema | 94.71 | 19.10 | 23 | 4819 | 3150 | 110581307 |
| Dry eye | 71.63 | 19.10 | 39 | 4803 | 55754 | 110528703 |
| Ulcerative keratitis | 71.50 | 19.10 | 20 | 4822 | 4746 | 110579711 |
| Eye pruritus | 68.88 | 19.10 | 32 | 4810 | 32743 | 110551714 |
| Diffuse lamellar keratitis | 66.75 | 19.10 | 8 | 4834 | 8 | 110584449 |
| Dacryostenosis acquired | 66.00 | 19.10 | 13 | 4829 | 671 | 110583786 |
| Foreign body sensation in eyes | 54.65 | 19.10 | 15 | 4827 | 3319 | 110581138 |
| Lacrimation increased | 52.23 | 19.10 | 26 | 4816 | 30924 | 110553533 |
| Photophobia | 50.56 | 19.10 | 24 | 4818 | 25747 | 110558710 |
| Corneal deposits | 49.52 | 19.10 | 10 | 4832 | 586 | 110583871 |
| Corneal striae | 47.24 | 19.10 | 7 | 4835 | 62 | 110584395 |
| Punctate keratitis | 42.52 | 19.10 | 10 | 4832 | 1194 | 110583263 |
| Corneal infiltrates | 41.73 | 19.10 | 8 | 4834 | 358 | 110584099 |
| Endophthalmitis | 41.39 | 19.10 | 15 | 4827 | 8172 | 110576285 |
| Visual impairment | 40.75 | 19.10 | 39 | 4803 | 134389 | 110450068 |
| Visual acuity reduced | 39.92 | 19.10 | 22 | 4820 | 32151 | 110552306 |
| Corneal disorder | 39.42 | 19.10 | 11 | 4831 | 2586 | 110581871 |
| Corneal dystrophy | 37.68 | 19.10 | 7 | 4835 | 264 | 110584193 |
| Corneal scar | 36.05 | 19.10 | 7 | 4835 | 335 | 110584122 |
| Eye swelling | 34.01 | 19.10 | 20 | 4822 | 33028 | 110551429 |
| Cataract | 33.93 | 19.10 | 28 | 4814 | 79457 | 110505000 |
| Ocular discomfort | 33.53 | 19.10 | 13 | 4829 | 8520 | 110575937 |
| Corneal opacity | 31.93 | 19.10 | 8 | 4834 | 1243 | 110583214 |
| Hypopyon | 30.82 | 19.10 | 8 | 4834 | 1432 | 110583025 |
| Cystoid macular oedema | 29.80 | 19.10 | 9 | 4833 | 2791 | 110581666 |
| Corneal perforation | 28.88 | 19.10 | 7 | 4835 | 949 | 110583508 |
| Giant papillary conjunctivitis | 28.82 | 19.10 | 4 | 4838 | 21 | 110584436 |
| Corneal thickening | 27.96 | 19.10 | 4 | 4838 | 27 | 110584430 |
| Abnormal sensation in eye | 27.51 | 19.10 | 8 | 4834 | 2178 | 110582279 |
| Visual acuity tests abnormal | 27.30 | 19.10 | 5 | 4837 | 174 | 110584283 |
| Eye inflammation | 25.83 | 19.10 | 11 | 4831 | 9160 | 110575297 |
| Glaucoma | 24.15 | 19.10 | 14 | 4828 | 22503 | 110561954 |
| Eye discharge | 23.01 | 19.10 | 10 | 4832 | 8744 | 110575713 |
| Corneal flap complication | 22.71 | 19.10 | 3 | 4839 | 10 | 110584447 |
| Corneal infection | 22.61 | 19.10 | 4 | 4838 | 114 | 110584343 |
| Dermatitis atopic | 22.52 | 19.10 | 14 | 4828 | 25527 | 110558930 |
| Corneal graft rejection | 22.08 | 19.10 | 4 | 4838 | 131 | 110584326 |
| Bladder cyst | 21.88 | 19.10 | 4 | 4838 | 138 | 110584319 |
| Corneal endothelial cell loss | 21.57 | 19.10 | 3 | 4839 | 16 | 110584441 |
| Toxic anterior segment syndrome | 20 | 19.10 | 7 | 4835 | 3447 | 110581010 |
| Undifferentiated connective tissue disease | 19.75 | 19.10 | 4 | 4838 | 238 | 110584219 |
| Product residue present | 19.10 | 19.10 | 7 | 4835 | 3934 | 110580523 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01BA14 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Corticosteroids, plain |
| ATC | S01CA12 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION Corticosteroids and antiinfectives in combination |
| FDA MoA | N0000175450 | Corticosteroid Hormone Receptor Agonists |
| FDA EPC | N0000175576 | Corticosteroid |
| MeSH PA | D018926 | Anti-Allergic Agents |
| CHEBI has role | CHEBI:35472 | anti-inflammatory drug |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:35679 | antilipemic drug |
Related Drugs by ATC class:
S01BA Corticosteroids, plain 15 drugs
S01CA Corticosteroids and antiinfectives in combination 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Herpes zoster keratoconjunctivitis | indication | 42448002 | |
| Punctate keratitis | indication | 42513006 | DOID:12197 |
| Iritis | indication | 65074000 | DOID:1406 |
| Perforation of cornea | indication | 74895004 | |
| Iridocyclitis | indication | 77971008 | |
| Corneal abrasion | indication | 85848002 | |
| Uveitis | indication | 128473001 | DOID:13141 |
| Ocular rosacea | indication | 200933006 | |
| Herpes zoster keratitis | indication | 397573005 | |
| Rosacea | indication | 398909004 | DOID:8881 |
| Anterior uveitis | indication | 410692006 | DOID:1407 |
| Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
| Post-Op Ocular Inflammation | indication | ||
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Herpes simplex dendritic keratitis | contraindication | 29943008 | |
| Fungal infection of eye | contraindication | 31194008 | |
| Tuberculosis of eye | contraindication | 49107007 | |
| Herpes zoster ophthalmicus | contraindication | 87513003 | |
| Viral eye infection | contraindication | 312132001 | |
| Vaccinia keratitis | contraindication | 397552005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.33 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1% | INVELTYS | ALCON LABS INC | N210565 | Aug. 22, 2018 | RX | SUSPENSION/DROPS | OPHTHALMIC | 10058511 | May 3, 2033 | A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER |
| 1% | INVELTYS | ALCON LABS INC | N210565 | Aug. 22, 2018 | RX | SUSPENSION/DROPS | OPHTHALMIC | 10864219 | May 3, 2033 | A METHOD FOR TREATING OCULAR INFLAMMATION |
| 1% | INVELTYS | ALCON LABS INC | N210565 | Aug. 22, 2018 | RX | SUSPENSION/DROPS | OPHTHALMIC | 11219597 | May 3, 2033 | A METHOD OF REDUCING POST-SURGICAL PAIN FOLLOWING OCULAR SURGERY |
| 1% | INVELTYS | ALCON LABS INC | N210565 | Aug. 22, 2018 | RX | SUSPENSION/DROPS | OPHTHALMIC | 11219597 | May 3, 2033 | A METHOD OF TREATING POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY |
| 1% | INVELTYS | ALCON LABS INC | N210565 | Aug. 22, 2018 | RX | SUSPENSION/DROPS | OPHTHALMIC | 12115246 | May 3, 2033 | A METHOD FOR THE TREATMENT OF POST-OPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY |
| 1% | INVELTYS | ALCON LABS INC | N210565 | Aug. 22, 2018 | RX | SUSPENSION/DROPS | OPHTHALMIC | 9056057 | May 3, 2033 | A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE |
| 1% | INVELTYS | ALCON LABS INC | N210565 | Aug. 22, 2018 | RX | SUSPENSION/DROPS | OPHTHALMIC | 9532955 | May 3, 2033 | A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE |
| 1% | INVELTYS | ALCON LABS INC | N210565 | Aug. 22, 2018 | RX | SUSPENSION/DROPS | OPHTHALMIC | 9737491 | May 3, 2033 | A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER |
| 1% | INVELTYS | ALCON LABS INC | N210565 | Aug. 22, 2018 | RX | SUSPENSION/DROPS | OPHTHALMIC | 9827191 | May 3, 2033 | A METHOD FOR TREATING INFLAMMATION AND/OR OTHER DISORDERS IN AN EYE OF A PATIENT |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 10058511 | May 3, 2033 | A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 10857096 | May 3, 2033 | A METHOD FOR TREATING DRY EYE IN A PATIENT |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 10940108 | May 3, 2033 | A METHOD FOR TREATING DRY EYE IN A PATIENT |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 10945948 | May 3, 2033 | A METHOD FOR TREATING DRY EYE IN A PATIENT |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 10993908 | May 3, 2033 | ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 11219596 | May 3, 2033 | A METHOD FOR TREATING DRY EYE IN A PATIENT |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 11596599 | May 3, 2033 | A METHOD FOR TREATING DRY EYE IN A PATIENT |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 12115246 | May 3, 2033 | A METHOD FOR TREATING DRY EYE IN A PATIENT |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 9056057 | May 3, 2033 | A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 9532955 | May 3, 2033 | A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 9737491 | May 3, 2033 | A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER |
| 0.25% | EYSUVIS | ALCON LABS INC | N210933 | Oct. 26, 2020 | RX | SUSPENSION/DROPS | OPHTHALMIC | 9827191 | May 3, 2033 | A METHOD FOR TREATING DRY EYE IN A PATIENT |
| 0.38% | LOTEMAX SM | BAUSCH AND LOMB INC | N208219 | Feb. 22, 2019 | RX | GEL | OPHTHALMIC | 11534395 | Jan. 26, 2036 | TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY |
| 0.38% | LOTEMAX SM | BAUSCH AND LOMB INC | N208219 | Feb. 22, 2019 | RX | GEL | OPHTHALMIC | 12589069 | Jan. 26, 2036 | TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY |
| 0.38% | LOTEMAX SM | BAUSCH AND LOMB INC | N208219 | Feb. 22, 2019 | RX | GEL | OPHTHALMIC | 10596107 | Dec. 23, 2036 | TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 0.5%;0.3% | LOTEPREDNOL ETABONATE AND TOBRAMYCIN | ALEMBIC | A217597 | Dec. 10, 2025 | RX | SUSPENSION/DROPS | OPHTHALMIC | July 14, 2026 | COMPETITIVE GENERIC THERAPY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucocorticoid receptor | Nuclear hormone receptor | AGONIST | DRUGBANK | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021086 | VUID |
| N0000179334 | NUI |
| D01689 | KEGG_DRUG |
| 4021086 | VANDF |
| 4024100 | VANDF |
| C0126177 | UMLSCUI |
| CHEMBL1200865 | ChEMBL_ID |
| D000069559 | MESH_DESCRIPTOR_UI |
| DB14596 | DRUGBANK_ID |
| 7085 | IUPHAR_LIGAND_ID |
| YEH1EZ96K6 | UNII |
| 444025 | PUBCHEM_CID |
| DB00873 | DRUGBANK_ID |
| 218087 | RXNORM |
| 11633 | MMSL |
| 315769 | MMSL |
| 4997 | MMSL |
| 007442 | NDDF |
| 007443 | NDDF |
| 108857005 | SNOMEDCT_US |
| 387047007 | SNOMEDCT_US |
| 419711001 | SNOMEDCT_US |
| CHEMBL1201389 | ChEMBL_ID |
| 129260-79-3 | SECONDARY_CAS_RN |
| 9865442 | PUBCHEM_CID |
| 6654 | INN_ID |
| Z8CBU6KR16 | UNII |
| CHEBI:50848 | CHEBI |
| Z8CBU6KR16 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Inveltys | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-9307 | SUSPENSION | 10 mg | OPHTHALMIC | NDA | 24 sections |
| LOTEPREDNOL ETABONATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-4080 | SUSPENSION/ DROPS | 2 mg | OPHTHALMIC | ANDA | 18 sections |
| LOTEPREDNOL ETABONATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-4135 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 17 sections |
| ALREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-007 | SUSPENSION/ DROPS | 2 mg | OPHTHALMIC | NDA | 20 sections |
| LOTEMAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-299 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | NDA | 17 sections |
| Alrex | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-353 | SUSPENSION/ DROPS | 2 mg | OPHTHALMIC | NDA | 20 sections |
| Zylet | HUMAN PRESCRIPTION DRUG LABEL | 2 | 24208-358 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | NDA | 21 sections |
| Lotemax | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-443 | OINTMENT | 5 mg | OPHTHALMIC | NDA | 22 sections |
| LOTEMAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-503 | GEL | 5 mg | OPHTHALMIC | NDA | 22 sections |
| Lotemax SM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-507 | GEL | 3.80 mg | OPHTHALMIC | NDA | 22 sections |
| Loteprednol Etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-508 | GEL | 5 mg | OPHTHALMIC | NDA authorized generic | 22 sections |
| Loteprednol etabonate and Tobramycin | Human Prescription Drug Label | 2 | 46708-801 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 21 sections |
| Loteprednol Etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-265 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 17 sections |
| ALREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4277 | SUSPENSION/ DROPS | 2 mg | OPHTHALMIC | NDA | 20 sections |
| LOTEMAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4278 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | NDA | 18 sections |
| LOTEPREDNOL ETABONATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1362 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 16 sections |
| loteprednol etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1366 | SUSPENSION/ DROPS | 2 mg | OPHTHALMIC | ANDA | 18 sections |
| loteprednol etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1367 | SUSPENSION/ DROPS | 2 mg | OPHTHALMIC | ANDA | 18 sections |
| Loteprednol etabonate and Tobramycin | Human Prescription Drug Label | 2 | 62332-801 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 21 sections |
| Loteprednol Etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62756-232 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 16 sections |
| Loteprednol Etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70244-034 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 17 sections |
| Loteprednol Etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70244-035 | SUSPENSION/ DROPS | 2 mg | OPHTHALMIC | ANDA | 17 sections |
| Loteprednol Etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70244-036 | GEL | 5 mg | OPHTHALMIC | ANDA | 23 sections |
| loteprednol etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70748-300 | SUSPENSION | 5 mg | OPHTHALMIC | ANDA | 14 sections |
| Inveltys | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71571-121 | SUSPENSION | 10 mg | TOPICAL | NDA | 24 sections |
| Eysuvis | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71571-333 | SUSPENSION/ DROPS | 2.50 mg | OPHTHALMIC | NDA | 23 sections |
| Loteprednol Etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72485-630 | GEL | 5 mg | OPHTHALMIC | ANDA | 23 sections |
| Loteprednol Etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72485-653 | SUSPENSION/ DROPS | 2 mg | OPHTHALMIC | ANDA | 17 sections |
| Loteprednol Etabonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72485-665 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 16 sections |
| LOTEPREDNOL ETABONATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72603-324 | SUSPENSION/ DROPS | 5 mg | OPHTHALMIC | ANDA | 17 sections |